AbbVie Inc (ABBV)
157.06
-1.20
(-0.76%)
USD |
NYSE |
May 24, 16:00
157.28
+0.22
(+0.14%)
After-Hours: 20:00
AbbVie Accounts Receivable (Quarterly): 11.95B for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 11.95B |
| December 31, 2023 | 11.16B |
| September 30, 2023 | 11.41B |
| June 30, 2023 | 11.49B |
| March 31, 2023 | 11.47B |
| December 31, 2022 | 11.25B |
| September 30, 2022 | 10.74B |
| June 30, 2022 | 11.24B |
| March 31, 2022 | 10.73B |
| December 31, 2021 | 9.977B |
| September 30, 2021 | 9.281B |
| June 30, 2021 | 9.914B |
| March 31, 2021 | 9.588B |
| December 31, 2020 | 8.822B |
| September 30, 2020 | 8.416B |
| June 30, 2020 | 8.354B |
| March 31, 2020 | 6.362B |
| December 31, 2019 | 5.428B |
| September 30, 2019 | 5.529B |
| June 30, 2019 | 5.482B |
| March 31, 2019 | 5.68B |
| December 31, 2018 | 5.384B |
| September 30, 2018 | 5.78B |
| June 30, 2018 | 5.793B |
| March 31, 2018 | 5.841B |
| Date | Value |
|---|---|
| December 31, 2017 | 5.088B |
| September 30, 2017 | 4.891B |
| June 30, 2017 | 4.859B |
| March 31, 2017 | 4.677B |
| December 31, 2016 | 4.758B |
| September 30, 2016 | 4.999B |
| June 30, 2016 | 5.048B |
| March 31, 2016 | 4.753B |
| December 31, 2015 | 4.73B |
| September 30, 2015 | 4.574B |
| June 30, 2015 | 4.367B |
| March 31, 2015 | 4.214B |
| December 31, 2014 | 3.735B |
| September 30, 2014 | 3.592B |
| June 30, 2014 | 3.684B |
| March 31, 2014 | 3.65B |
| December 31, 2013 | 3.854B |
| September 30, 2013 | 3.798B |
| June 30, 2013 | 3.755B |
| March 31, 2013 | 4.299B |
| December 31, 2012 | 4.298B |
| September 30, 2012 | 3.098B |
| June 30, 2012 | 2.994B |
| March 31, 2012 | 3.647B |
| December 31, 2011 | 3.817B |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
5.428B
Minimum
Dec 2019
11.95B
Maximum
Mar 2024
9.43B
Average
9.946B
Median
Accounts Receivable (Quarterly) Benchmarks
| Amgen Inc | 6.776B |
| Johnson & Johnson | 14.95B |
| Eli Lilly and Co | 7.886B |
| Merck & Co Inc | 11.37B |
| Pfizer Inc | 10.99B |